AN2 Therapeutics entered into a $80 million at-the-market sales agreement with Jefferies LLC and terminated its prior TD Cowen agreement after selling $20 million of common stock.
Key takeaways
Entered Open Market Sale Agreement with Jefferies LLC for up to $80 million of common stock.
Sales through Jefferies as agent via at-the-market offerings on Nasdaq Global Select Market.
Jefferies commission up to 3.0% of gross proceeds with customary indemnification.
Terminated prior TD Cowen Sales Agreement effective April 9, 2026.
Under prior agreement, sold 2,502,000 shares for $20,016,251 aggregate offering price.